Huang et al. found that mutations of KRAS, TP53, SMAD4, and BRAF were associated with CRC metastasis and may be both potential biomarkers of metastasis as well as a therapeutic target in CRC [2]. Here, SMAD4 is linked to colorectal carcinoma.